4-Aminoquinoline derivatives, useful as anti-inflammatory agents

• US 4,235,908 A
• Filed: 04/09/1979
• Issued: 11/25/1980
• Est. Priority Date: 05/24/1978
• Status: Expired due to Term

• Current Assignee: John Wyeth & Brother Limited (Pfizer Inc.)
• Original Assignee: John Wyeth & Brother Limited (Pfizer Inc.)
• Inventors: Boyle, John T. A.
• Primary Examiner(s): Daus, Donald G.
• Assistant Examiner(s): Rivers, Diana G.
• Application Number:
  US06/028,617
• Time in Patent Office: 596 Days
• Field of Search: 546/160, 546/161, 424/258
• US Class Current: 514/313
• CPC Class Codes: C07D 215/44 with aryl radicals attached to said nitrogen atoms

Abstract

New 4-aminoquinoline derivatives having the formula ##STR1## wherein X is halogen or trifluoromethyl at the designated 7- or 8-position; Z is hydrogen, halogen, lower alkyl, lower alkoxy, nitro, di(lower alkyl)amino or trifluoromethyl, n is from 1 to 4, R¹ is hydrogen or lower alkyl, R² is lower alkyl, R³ is lower alkyl and A is lower alkylene, and their pharmaceutically acceptable acid addition salts show anti-inflammatory activity.

Claims

1. A compound selected from those having the formula ##STR8## and their pharmaceutically acceptable acid addition salts, wherein X is at the designated 7- or 8-position and represents a substituent selected from trifluoromethyl and halogen, Z represents a member of the group consisting of hydrogen, halogen, lower alkyl, lower alkoxy, nitro, di(lower alkyl)amino and trifluoromethyl, n represents an integer from 1 to 4 and R represents a group selected from those having the formulae

View Dependent Claims (2, 3, 4, 5)

2. A compound as defined in claim 1, which is 2-[4-(7-chloro-4-quinolylamino)phenyl]-N-(1-ethyl-3-piperidyl)acetamide or a pharmaceutically acceptable acid addition salt thereof.

3. A compound as defined in claim 1, which is 2-[4-(7-chloro-4-quinolylamino)phenyl]-N-(2-diethylaminoethyl)-N-ethylacetamide or a pharmaceutically acceptable acid addition salt thereof.

4. A pharmaceutical composition useful as an anti-inflammatory agent, which comprises a compound as defined in claim 1 and a pharmaceutically acceptable, non-toxic carrier.

5. A method of treating inflammation in a mammal which comprises administering to said mammal an effective anti-inflammatory amount of a compound as claimed in claim 1 or a pharmaceutically acceptable acid addition salt thereof.